• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.肺炎链球菌DNA拓扑异构酶IV的ParC亚基是氟喹诺酮类药物的主要作用靶点,并与DNA回旋酶A亚基协同形成耐药表型。
Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.
2
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析:在氟喹诺酮耐药性中的作用
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
3
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.拓扑异构酶IV和DNA促旋酶作为环丙沙星在肺炎链球菌中的作用靶点。
Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321.
4
Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.肺炎链球菌GyrA和ParC蛋白中的喹诺酮耐药性突变:基于酶分析、细胞内水平以及野生型和突变型蛋白表型对喹诺酮作用机制的深入了解
Antimicrob Agents Chemother. 2001 Nov;45(11):3140-7. doi: 10.1128/AAC.45.11.3140-3147.2001.
5
Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.草绿色链球菌临床分离株的parC、parE和gyrA基因中的氟喹诺酮耐药突变
Antimicrob Agents Chemother. 1998 Nov;42(11):2792-8. doi: 10.1128/AAC.42.11.2792.
6
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.gyrA和parC基因突变对体内外获得的肺炎链球菌突变体氟喹诺酮耐药性的影响。
Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
7
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.新型氟喹诺酮类药物对肺炎链球菌临床分离株的活性,包括那些gyrA、parC和parE基因座发生突变的分离株。
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
8
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.DNA 回旋酶和拓扑异构酶IV是环丙沙星作用于肺炎链球菌的双重靶点。
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
9
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.肺炎链球菌中拓扑异构酶IV和DNA促旋酶突变对新型氟喹诺酮类药物耐药性的影响
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
10
Molecular bases of three characteristic phenotypes of pneumococcus: optochin-sensitivity, coumarin-sensitivity, and quinolone-resistance.肺炎球菌三种特征性表型的分子基础:对奥普托欣敏感、对香豆素敏感和对喹诺酮耐药。
Microb Drug Resist. 1997 Summer;3(2):177-93. doi: 10.1089/mdr.1997.3.177.

引用本文的文献

1
CRISPRi-TnSeq maps genome-wide interactions between essential and non-essential genes in bacteria.CRISPRi-TnSeq 绘制了细菌中必需基因和非必需基因之间的全基因组相互作用图谱。
Nat Microbiol. 2024 Sep;9(9):2395-2409. doi: 10.1038/s41564-024-01759-x. Epub 2024 Jul 19.
2
favors tolerance via metabolic adaptation over resistance to circumvent fluoroquinolones.有利于通过代谢适应而不是耐药来规避氟喹诺酮类药物。
mBio. 2024 Feb 14;15(2):e0282823. doi: 10.1128/mbio.02828-23. Epub 2024 Jan 9.
3
Genome-wide mapping of fluoroquinolone-stabilized DNA gyrase cleavage sites displays drug specific effects that correlate with bacterial persistence.全基因组范围内氟喹诺酮稳定的 DNA 回旋酶切割位点的作图显示与细菌持续存在相关的药物特异性效应。
Nucleic Acids Res. 2023 Feb 22;51(3):1208-1228. doi: 10.1093/nar/gkac1223.
4
Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.喹诺酮类的生物学效应:一类广谱抗菌药物。
Molecules. 2021 Nov 25;26(23):7153. doi: 10.3390/molecules26237153.
5
Evolutionary Pathways and Trajectories in Antibiotic Resistance.抗生素耐药性的进化途径和轨迹。
Clin Microbiol Rev. 2021 Dec 15;34(4):e0005019. doi: 10.1128/CMR.00050-19. Epub 2021 Jun 30.
6
Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.DNA 拓扑异构酶 I 抑制剂对肺炎链球菌的抗菌活性与氟喹诺酮类药物的比较。
PLoS One. 2020 Nov 3;15(11):e0241780. doi: 10.1371/journal.pone.0241780. eCollection 2020.
7
Mutant Prevention Concentration of Ciprofloxacin against Clinical Isolates: An Ideal Prognosticator in Treating Multidrug-Resistant Strains.环丙沙星对临床分离株的突变预防浓度:治疗多重耐药菌株的理想预后指标。
Int J Microbiol. 2019 Oct 20;2019:6850108. doi: 10.1155/2019/6850108. eCollection 2019.
8
Upregulation of the PatAB Transporter Confers Fluoroquinolone Resistance to .PatAB转运蛋白的上调赋予了……对氟喹诺酮的抗性。 (原文句子不完整,缺少具体的对象)
Front Microbiol. 2017 Oct 26;8:2074. doi: 10.3389/fmicb.2017.02074. eCollection 2017.
9
The Transcriptome of Induced by Local and Global Changes in Supercoiling.由超螺旋的局部和全局变化诱导的转录组。
Front Microbiol. 2017 Jul 31;8:1447. doi: 10.3389/fmicb.2017.01447. eCollection 2017.
10
Absence of tmRNA Has a Protective Effect against Fluoroquinolones in .缺乏转运信使核糖核酸(tmRNA)对氟喹诺酮类药物具有保护作用。 (原句结尾不完整,推测补充了这部分以使译文完整通顺)
Front Microbiol. 2017 Jan 10;7:2164. doi: 10.3389/fmicb.2016.02164. eCollection 2016.

本文引用的文献

1
Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.空肠弯曲菌gyrA基因的克隆、核苷酸序列及喹诺酮耐药性突变的特征分析
Antimicrob Agents Chemother. 1993 Mar;37(3):457-63. doi: 10.1128/AAC.37.3.457.
2
Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.大肠杆菌拓扑异构酶IV。纯化、特性、亚基结构及亚基相互作用
J Biol Chem. 1993 Nov 15;268(32):24481-90.
3
Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.多重耐药病原菌。洛克菲勒大学研讨会报告。
N Engl J Med. 1994 Apr 28;330(17):1247-51. doi: 10.1056/NEJM199404283301725.
4
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.结核分枝杆菌gyrA和gyrB基因的克隆、核苷酸序列测定及喹诺酮耐药性突变检测
Antimicrob Agents Chemother. 1994 Apr;38(4):773-80. doi: 10.1128/AAC.38.4.773.
5
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构:氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
6
Molecular basis of the optochin-sensitive phenotype of pneumococcus: characterization of the genes encoding the F0 complex of the Streptococcus pneumoniae and Streptococcus oralis H(+)-ATPases.肺炎球菌对奥普托欣敏感表型的分子基础:肺炎链球菌和口腔链球菌H(+) -ATP酶F0复合物编码基因的特征分析
Mol Microbiol. 1994 May;12(4):587-98. doi: 10.1111/j.1365-2958.1994.tb01045.x.
7
Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.淋病奈瑟菌在耐氟喹诺酮类药物的分离株中,gyrA和parC的类似区域会发生突变。
Mol Microbiol. 1994 Oct;14(2):371-80. doi: 10.1111/j.1365-2958.1994.tb01297.x.
8
The twisted 'life' of DNA in the cell: bacterial topoisomerases.细胞中DNA的“扭曲”生命:细菌拓扑异构酶
Mol Microbiol. 1995 Feb;15(4):601-6. doi: 10.1111/j.1365-2958.1995.tb02369.x.
9
Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance.肺炎链球菌DNA促旋酶B亚基中丝氨酸127到亮氨酸的替换与新生霉素耐药性有关。
J Bacteriol. 1995 Jul;177(14):4166-70. doi: 10.1128/jb.177.14.4166-4170.1995.
10
Studies on transformation of Escherichia coli with plasmids.大肠杆菌质粒转化的研究。
J Mol Biol. 1983 Jun 5;166(4):557-80. doi: 10.1016/s0022-2836(83)80284-8.

肺炎链球菌DNA拓扑异构酶IV的ParC亚基是氟喹诺酮类药物的主要作用靶点,并与DNA回旋酶A亚基协同形成耐药表型。

ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.

作者信息

Muñoz R, De La Campa A G

机构信息

(Consejo Superior de Investigaciones Cientificas), Centro Nacional de Biologia Celular y Retrovirus, Instituto de Salud Carlos III, Madrid, Spain.

出版信息

Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252.

DOI:10.1128/AAC.40.10.2252
PMID:8891124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC163513/
Abstract

The genes encoding the ParC and ParE subunits of topoisomerase IV of Streptococcus pneumoniae, together with the region encoding amino acids 46 to 172 (residue numbers are as in Escherichia coli) of the pneumococcal GyrA subunit, were partially characterized. The gyrA gene maps to a physical location distant from the gyrB and parC loci on the chromosome, whereas parC is closely linked to parE. Ciprofloxacin-resistant (Cpr) clinical isolates of S. pneumoniae had mutations affecting amino acid residues of the quinolone resistance-determining region of ParC (low-level Cpr) or in both quinolone resistance-determining regions of ParC and GyrA (high-level Cpr). Mutations were found in residue positions equivalent to the serine at position 83 and the aspartic acid at position 87 of the E. coli GyrA subunit. Transformation experiments suggest that ParC is the primary target of ciprofloxacin. Mutation in parC appears to be a prerequisite before mutations in gyrA can influence resistance levels.

摘要

对肺炎链球菌拓扑异构酶IV的ParC和ParE亚基的编码基因,以及肺炎球菌GyrA亚基编码氨基酸46至172(残基编号与大肠杆菌中的相同)的区域进行了部分表征。gyrA基因定位于染色体上与gyrB和parC基因座距离较远的物理位置,而parC与parE紧密相连。肺炎链球菌的环丙沙星耐药(Cpr)临床分离株存在影响ParC喹诺酮耐药决定区氨基酸残基的突变(低水平Cpr),或ParC和GyrA的喹诺酮耐药决定区均发生突变(高水平Cpr)。在与大肠杆菌GyrA亚基第83位丝氨酸和第87位天冬氨酸等效的残基位置发现了突变。转化实验表明,ParC是环丙沙星的主要靶点。parC中的突变似乎是gyrA中的突变能够影响耐药水平之前的一个先决条件。